News & Insights

Cases & Deals

June 1, 2020

Alexion Pharmaceuticals Secures Favorable Resolution and Termination of Challenge to SOLIRIS® Patents

King & Spalding represented Alexion Pharmaceuticals in resolving three inter partes review (“IPR”) challenges by Amgen Inc. to patents covering SOLIRIS® (eculizumab), Alexion’s blockbuster antibody treatment for rare diseases including the life-threatening disorder paroxysmal nocturnal hemoglobinuria.  The IPRs were terminated following a settlement agreement permitting Amgen to sell an eculizumab product in the U.S. starting March 1, 2025.  SOLIRIS® is Alexion’s top-selling product, with over $4 billion in worldwide sales.  Alexion was represented by King & Spalding partners Gerald Flattmann, Vanessa Yen, Evan Diamond, and Lori Gordon, and associates Julia Kolibachuk, Nick Choi, Andrew Cochran, and Jesse Snyder.